APAC

Lipid nanoparticles market to reach $3.1b by 2033 as chronic diseases rise

The adoption of mRNA-based vaccines will also fuel demand.

Reproductive health disorders to drive female tech market to $26.1b by 2033

It will expand at a compound annual growth rate of 15.2%.

Nanomedicine market poised for double-digit growth

It is driven by the rising prevalence of chronic diseases.

Neurological disorders and aging boost brain-computer interface market

Government and private investment accelerates innovation.

AI and mobile integration drive surge in smart inhaler adoptions

Rising need for personalised and remote healthcare also drives adoption.

Structural heart devices market to reach $2.93b by 2032

Asia Pacific is the fastest-growing region with a 10.0% CAGR.

Rising CKD cases and advanced biomarkers fuel $4.8b market growth

Market growth is expected to continue through 2034.

Global prescription drugs market to reach $2.26t by 2034

The Asia Pacific region is projected to register the fastest growth rate.

Rising cases, advanced diagnostics drive biliary tract cancer market growth across 7MM

Increasing cases were driven by aging populations and liver diseases.

How quickly can hospitals expand ICU and acute-care beds to meet rising demand?

A staffing shortage makes it harder to turn added space into fully usable beds.

Rising demand for advanced surgical devices to push market to $27.4b by 2032

Robotic-assisted surgery drives precision in complex procedures.

Automation, continuous manufacturing drive global pharmaceutical equipment demand

It is also driven by chronic diseases and biologics production.

Aging population drives demand for durable medical equipment market

Telehealth, 3D printing, and customisation are amongst the key trends.

Pureland Venture’s Chris Hardesty: Governments must sustain long-term focus on healthcare innovation, technology

He discusses how healthcare systems in Asia Pacific need to evolve beyond simply expanding coverage and towards delivering equitable, sustainable, and high-impact care.

SLE, lupus nephritis market to more than double by 2034

It will be driven by nine new pipeline therapies targeting disease modification